Global R&D Heads Talk Superbugs, PROTACs And More
Risk Is Essential To Discovery
A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery
You may also be interested in...
Pfizer's India MD On Funding Healthcare Startups
Pfizer’s India managing director, S Sridhar, talks to Scrip about funding startups focused on oncology and digital health, via the CSR route. Two such startups, SiCureMi and Tinkertech, are close to commercialization. Meanwhile, Pfizer's pact with MPP will allow the COVID-19 antiviral Paxlovid to find its way to India and 94 other low- and middle-income countries
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: CAR-Ts move into earlier treatment; Sanofi bets big on super antibodies; takeaways from the world’s largest dermatology conference; China moves towards imported COVID vaccines; and R&D experts discuss the superbug threat.
Accenture Sees AI Solutions For IDMP Compliance, Trial Efficiency
AI could help companies comply with regulations like GDPR and IDMP, apart from optimizing clinical trial processes, Accenture’s managing director leading R&D analytics in North America says, as he lists cases where the firm drove cost savings.